U.S. regulators have delayed a decision on a proposed new anti-clotting drug from Bristol-Myers Squib Co. (BMY) and Pfizer Inc. (PFE) by three months to June 28, after the companies provided new information to the agency.
Bristol-Myers and Pfizer didn't specify what new information they submitted, but any delay in the introduction of the drug--Eliquis--may reduce 2012 sales versus Wall Street expectations. Sanford Bernstein analyst Tim Anderson had been expecting sales of Eliquis to total $395 million for 2012, but said Thursday that this estimate may have to be revised slightly.
Thursday, March 01, 2012
US FDA Delays Decision On Bristol/Pfizer Anti-Clot Drug | Fox Business